BioLineRx (BLRX) Current Assets (2021 - 2025)

BioLineRx has reported Current Assets over the past 5 years, most recently at $23.7 million for Q4 2025.

  • Quarterly results put Current Assets at $23.7 million for Q4 2025, down 12.63% from a year ago — trailing twelve months through Dec 2025 was $23.7 million (down 12.63% YoY), and the annual figure for FY2025 was $23.7 million, down 12.63%.
  • Current Assets for Q4 2025 was $23.7 million at BioLineRx, down from $27.1 million in the prior quarter.
  • Over the last five years, Current Assets for BLRX hit a ceiling of $57.4 million in Q4 2021 and a floor of $23.7 million in Q4 2025.
  • Median Current Assets over the past 5 years was $47.2 million (2023), compared with a mean of $41.5 million.
  • Biggest five-year swings in Current Assets: decreased 9.27% in 2023 and later crashed 42.56% in 2024.
  • BioLineRx's Current Assets stood at $57.4 million in 2021, then dropped by 9.41% to $52.0 million in 2022, then decreased by 9.27% to $47.2 million in 2023, then crashed by 42.56% to $27.1 million in 2024, then fell by 12.63% to $23.7 million in 2025.
  • The last three reported values for Current Assets were $23.7 million (Q4 2025), $27.1 million (Q4 2024), and $47.2 million (Q4 2023) per Business Quant data.